摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

4-(4-Amino-piperidin-1-yl)-benzonitrile | 281234-90-0

中文名称
——
中文别名
——
英文名称
4-(4-Amino-piperidin-1-yl)-benzonitrile
英文别名
4-(4-aminopiperidin-1-yl)benzonitrile;4-amino-1-(4-cyanophenyl)-piperidine
4-(4-Amino-piperidin-1-yl)-benzonitrile化学式
CAS
281234-90-0
化学式
C12H15N3
mdl
MFCD11038429
分子量
201.271
InChiKey
IPHZXPNIIVSIEK-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 沸点:
    385.0±37.0 °C(Predicted)
  • 密度:
    1.15±0.1 g/cm3(Predicted)

计算性质

  • 辛醇/水分配系数(LogP):
    1.4
  • 重原子数:
    15
  • 可旋转键数:
    1
  • 环数:
    2.0
  • sp3杂化的碳原子比例:
    0.416
  • 拓扑面积:
    53
  • 氢给体数:
    1
  • 氢受体数:
    3

上下游信息

  • 上游原料
    中文名称 英文名称 CAS号 化学式 分子量
  • 下游产品
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

  • 作为反应物:
    参考文献:
    名称:
    Substituted (aminoiminomethyl or aminomethyl) benzoheteroaryl compounds
    摘要:
    这项发明涉及一种化合物,其化学式为I,该化合物是(aminoiminomethyl或aminomethyl)benzoheteroaryl化合物,可通过将该化合物与含有凝血因子Xa的组合物结合来抑制凝血因子Xa的活性。本发明还涉及含有化合物I的组合物、其制备方法以及它们的用途,如用于抑制凝血酶的形成或用于治疗患有与生理上有害的凝血酶过量相关的疾病状态的患者。
    公开号:
    US06541505B1
  • 作为产物:
    描述:
    4-叠氮基哌啶-1-羧酸叔丁酯盐酸 、 10% Pt/activated carbon 、 氢气potassium carbonate 作用下, 以 1,4-二氧六环甲醇二甲基亚砜 为溶剂, 反应 18.0h, 生成 4-(4-Amino-piperidin-1-yl)-benzonitrile
    参考文献:
    名称:
    Disubstituted 1-Aryl-4-Aminopiperidine Library Synthesis Using Computational Drug Design and High-Throughput Batch and Flow Technologies
    摘要:
    A platform that incorporates computational library design, parallel solution-phase synthesis, continuous flow hydrogenation, and automated high throughput purification and reformatting technologies was applied to the production of a 120-member library of 1-aryl-4-amino-piperidine analogues for drug discovery screening. The application described herein demonstrates the advantages of computational library design coupled with a flexible, modular approach to library synthesis. The enabling technologies described can be readily adopted by the traditional medicinal chemist without extensive training and lengthy process development times.
    DOI:
    10.1021/co400078r
点击查看最新优质反应信息

文献信息

  • Non-nucleoside reverse transcriptase inhibitors
    申请人:Kestesz Denis John
    公开号:US20080146595A1
    公开(公告)日:2008-06-19
    The present invention provides for compounds useful for treating an HIV infection, or preventing an HIV infection, or treating AIDS or ARC. The compounds of the invention are of formula I wherein R 1 , R 2 , R 3 , R 4 , R 5a , R 5b , R 6a , R 6b and X are as herein defined. Also disclosed in the present invention are methods of treating an HIV infection with compounds defined herein and pharmaceutical compositions containing said compounds.
    本发明提供了用于治疗HIV感染、预防HIV感染、治疗AIDS或ARC的化合物。本发明的化合物具有如下式I所示的结构,其中R1、R2、R3、R4、R5a、R5b、R6a、R6b和X的定义如本文所述。本发明还公开了使用上述定义的化合物治疗HIV感染的方法,以及含有这些化合物的药物组合物。
  • Cinnamide compound
    申请人:Kimura Teiji
    公开号:US20060004013A1
    公开(公告)日:2006-01-05
    The present invention relates to a compound represented by Formula (I): (wherein Ar 1 represents an imidazolyl group which may be substituted with 1 to 3 substituents; Ar 2 represents a pyridinyl group, a pyrimidinyl group, or a phenyl group which may be substituted with 1 to 3 substituents; X 1 represents (1) —C≡C— or (2) a double bond etc. which may be substituted; R 1 and R 2 represent, for example, a C1-6 alkyl group or C3-8 cycloalkyl group which may be substituted) or a pharmacologically acceptable salt thereof and to the use thereof as pharmaceutical agents. The object of the present invention is to find a therapeutic or preventive agent for diseases caused by Aβ. According to the present invention, a therapeutic or preventive agents for diseases caused by Aβ can be provided.
    本发明涉及一种由式(I)表示的化合物:(其中Ar1代表可以被1到3个取代基取代的咪唑基团;Ar2代表可以被1到3个取代基取代的吡啶基团、嘧啶基团或苯基;X1代表(1)-C≡C-或(2)可以被取代的双键等;R1和R2代表,例如,可以被取代的C1-6烷基或C3-8环烷基等)或其药理学上可接受的盐,并且用作药物剂。本发明的目的是寻找一种治疗或预防由Aβ引起的疾病的药剂。根据本发明,可以提供治疗或预防由Aβ引起的疾病的药剂。
  • Carboxylic acid derivatives, pharmaceutical compositions containing
    申请人:Dr. Karl Thomae GmbH
    公开号:US05442064A1
    公开(公告)日:1995-08-15
    The invention relates to carboxylic acid derivatives of general formula A--B--C--D--E--F--G (I) wherein A to G are defined as in claim 1, the tautomers thereof, the stereoisomers thereof including the mixtures thereof and the addition salts thereof, particularly the physiologically acceptable salts with inorganic or organic acids or bases, which have valuable pharmacological properties, preferably inhibitory effects on aggregation, and to pharmaceutical compositions containing the compounds and processes for preparing them.
    本发明涉及一种通式为A--B--C--D--E--F--G (I) 的羧酸生物,其中A至G如权利要求1所定义,其互变异构体、立体异构体及其混合物和加成盐,特别是与无机或有机酸或碱物理上可接受的盐,具有有价值的药理学性质,优选抑制聚集的效果,并且涉及包含该化合物的制药组合物和制备它们的方法。
  • Phenoxypropanolamines, method for producing them and pharmaceutical compositions containning them
    申请人:——
    公开号:US20030040530A1
    公开(公告)日:2003-02-27
    The invention relates to compounds of formula (I) 1 where R 1 represents a hydrogen or halogen atom or an —S(O) z —(C 1 -C 4 )alkyl, —S(O) z —(C 1 -C 4 )R 3 , —SO 2 —NH—(C 1 -C 4 )alkyl, —NHCO(C 1 -C 4 ) alkyl, —CO(C 1 -C 4 )alkyl or —NHSO 2 —(C 1 -C 4 )alkyl group; m and n independently represent 0, 1 or 2; A represents a group of formula (a) or (b): 2 where X is N or CH; R 2 represents an —SO 2 —R 3 , —CO—R 3 or —CO—(C 1 -C 4 )—alkyl group; R 3 represents a phenyl group, optionally substituted by a (C 1 -C 4 )alkyl or (C 1 -C 4 )alkoxy group, one or two halogen atoms or a heterocycle; R 4 represents a hydrogen or halogen atom or a (C 1 -C 6 )alkyl, (C 1 -C 4 )alkoxy, —COOH, —COO(C 1 -C 4 )alkyl, —CN, —CONR 5 R 6 , —NO 2 , —NHSO 2 (C 1 -C 4 )alkyl or —SO 2 NR 5 R 6 group; z is 1 or 2; R 5 and R 6 independently represent a hydrogen atom or a (C 1 -C 4 )alkyl, phenyl or phenyl (C 1 -C 4 )alkyl group; and their salts or solvates, to a process for their preparation, to synthetic intermediates and to the pharmaceutical compositions comprising them.
    本发明涉及式(I)的化合物:其中,R1代表氢原子或卤素原子,或者-S(O)z-(C1-C4)烷基,-S(O)z-(C1-C4)R3,-SO2-NH-(C1-C4)烷基,-NHCO(C1-C4)烷基,-CO(C1-C4)烷基或-NHSO2-(C1-C4)烷基;m和n独立地表示0、1或2;A表示式(a)或(b)的基团:其中X为N或CH;R2表示-SO2-R3,-CO-R3或-CO-(C1-C4)-烷基;R3表示苯基,可选地被(C1-C4)烷基或(C1-C4)烷氧基,一个或两个卤素原子或杂环基取代;R4表示氢原子或卤素原子,或(C1-C6)烷基,(C1-C4)烷氧基,-COOH,-COO(C1-C4)烷基,-CN,-CONR5R6,-NO2,-NHSO2(C1-C4)烷基或-SO2NR5R6基团;z为1或2;R5和R6独立地表示氢原子或(C1-C4)烷基,苯基或苯基(C1-C4)烷基;以及它们的盐或溶剂合物,它们的制备方法,合成中间体和包含它们的制药组合物。
  • Fluoropyrrolidines as dipeptidyl peptidase inhibitors
    申请人:——
    公开号:US20040242636A1
    公开(公告)日:2004-12-02
    The present invention relates to novel compounds, their use for inhibiting post prolin/analine-cleaving proteases, such as serine proteases, such as dipeptidyl peptidases, such as dipeptidyl peptidase IV (DPP-IV), and to methods for their production and their therapeutic utility.
    本发明涉及新颖化合物,其用于抑制后脯酸/苯丙酸剪切蛋白酶,例如丝氨酸蛋白酶,例如二肽基肽酶,例如二肽基肽酶IV(DPP-IV),以及其生产方法和治疗效用。
查看更多

同类化合物

(R)-3-甲基哌啶盐酸盐; (R)-2-苄基哌啶-1-羧酸叔丁酯 ((3S,4R)-3-氨基-4-羟基哌啶-1-基)(2-(1-(环丙基甲基)-1H-吲哚-2-基)-7-甲氧基-1-甲基-1H-苯并[d]咪唑-5-基)甲酮盐酸盐 高氯酸哌啶 高托品酮肟 马来酸帕罗西汀 颜料红48:4 顺式3-氟哌啶-4-醇盐酸盐 顺式2,6-二甲基哌啶-4-酮 顺式1-苄基-4-甲基-3-甲氨基-哌啶 顺式-叔丁基4-羟基-3-甲基哌啶-1-羧酸酯 顺式-6-甲基-哌啶-1,3-二甲酸1-叔丁酯 顺式-5-(三氟甲基)哌啶-3-羧酸甲酯盐酸盐 顺式-4-叔丁基-2-甲基哌啶 顺式-4-Boc-氨基哌啶-3-甲酸甲酯 顺式-4-(氮杂环丁烷-1-基)-3-氟哌 顺式-3-顺式-4-氨基哌啶 顺式-3-甲氧基-4-氨基哌啶 顺式-3-BOC-3,7-二氮杂双环[4.2.0]辛烷 顺式-3-(1-吡咯烷基)环丁腈 顺式-3,5-哌啶二羧酸 顺式-3,4-二溴-3-甲基吡咯烷盐酸盐 顺式-2,6-二甲基-4-氧代哌啶-1-羧酸叔丁基酯 顺式-1-叔丁氧羰基-4-甲基氨基-3-羟基哌啶 顺式-1-boc-3,4-二氨基哌啶 顺式-1-(4-叔丁基环己基)-4-苯基-4-哌啶腈 顺式-1,3-二甲基-4-乙炔基-6-苯基-3,4-哌啶二醇 顺-4-(4-氟苯基)-1-(4-异丙基环己基)-4-哌啶羧酸 顺-4-(2-氟苯基)-1-(4-异丙基环己基)-4-哌啶羧酸 顺-3-氨基-4-氟哌啶-1-羧酸叔丁酯 顺-1-苄基-4-甲基哌啶-3-氨基酸甲酯盐酸盐 非莫西汀 雷芬那辛 雷拉地尔 阿维巴坦中间体4 阿格列汀杂质 阿尼利定盐酸盐 CII 阿尼利定 阿塔匹酮 阿哌沙班杂质BMS-591455 阿哌沙班杂质87 阿哌沙班杂质52 阿哌沙班杂质51 阿哌沙班杂质5 阿哌沙班杂质 阿哌沙班杂质 阿哌沙班-d3 阿哌沙班 阻聚剂701 间氨基谷氨酰胺